Your browser doesn't support javascript.
loading
Making safe sense of an anti-sense!
Gill, Upkar S; Lemoine, Maud.
Affiliation
  • Gill US; Blizard Institute, Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Lemoine M; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, St Mary's Hospital London, UK.
Cell Rep Med ; 3(1): 100503, 2022 01 18.
Article in En | MEDLINE | ID: mdl-35106512
ABSTRACT
Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al.1 report on the safety and antiviral efficacy of this agent. We "spotlight" key findings of this study and its impact for future clinical trial design.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country: